Appointed CEO has Purchased Shares in Stille
Stille AB reports that Torbjörn Sköld, incoming CEO starting March 20th, 2023, purchased 8,770 shares in Stille on January 31st, 2023. The shares were purchased at 114 SEK per share, with a total value of 997,780 SEK.
Torshälla, February 2nd, 2023.
For more information, please contact:
Interim CEO and President
+46 (0)73 087 49 70 | [email protected]
Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, [email protected] For more information, visit www.stille.se.
Studie med gentestet Prostatype® publicerat i ledande internationell tidskrift
Studien som genomförts av ett forskningsteam på Akademiska sjukhuset i Uppsala under ledning av docent och överläkare Michael Häggman visar att gentestet Prostatype® korrekt bedömer prostatacancertumörens aggressivitet när man jämför genuttryck från vävnadsprover, så kallade biopsier, med ”fac...
ViroGates announces its Annual Report 2022: Growing revenue by 33% and more than tripling the customer base in clinical routine
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Annual Report for the period 1 January – 31 December 2022, as approved today by the company’s Board of Directors....
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 10.00
On 20 December 2022 AegirBio AB (“AegirBio” or the “Company”) announced that the Company had agreed on a convertible financing agreement with Atlas Special Opportunities, LLC (“Atlas”) regarding convertible bonds amounting to MSEK 55.00 (the “Convertible Bonds”) with attached warrants. On 20Ja...
AegirBio AB: Atlas Special Opportunities, LLC påkallar partiell konvertering av utestående konvertibler till ett nominellt belopp om 10,00 MSEK
Den 20 december 2022 meddelade AegirBio AB (”AegirBio” eller ”Bolaget”) att Bolaget avtalat om en konvertibelfinansiering med Atlas Special Opportunities, LLC (”Atlas”) avseende konvertibler om 55,00MSEK (”Konvertiblerna”) med vidhängande teckningsoptioner. Bolagsstämman beslutade den 20...